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Summary. Background: Proteases expressed in athero-
sclerotic plaque lesions generate collagen fragments,
release glycosaminoglycans (chondroitin sulfate [CS] and
dermatan sulfate [DS]) and expose extracellular matrix
(ECM) proteins (e.g. decorin) at sites of fibrin formation.
Objective: Here we address the effect of these vessel wall
components on the lysis of fibrin by the tissue
plasminogen activator (tPA)/plasminogen system and on
the mechanical stability of clots. Methods and results:
MMP-8-digested collagen fragments, isolated CS, DS,
glycosylated decorin and its core protein were used to
prepare mixed matrices with fibrin (additives present at a
50-fold lower mass concentration than fibrinogen).
Scanning electron microscopy (SEM) showed that the
presence of ECM components resulted in a coarse fibrin
structure, most pronounced for glycosylated decorin
causing an increase in the median fiber diameter from 85
to 187 nm. Rheological measurements indicated that
these structural alterations were coupled to decreased
shear resistance (1.8-fold lower shear stress needed for
gel/fluid transition of the clots containing glycosylated
decorin) and rigidity (reduction of the storage modulus
from 54.3 to 33.2 Pa). The lytic susceptibility of the
modified fibrin structures was increased. The time to 50%
lysis by plasmin was reduced approximately 2-fold for all
investigated ECM components (apart from the core
protein of decorin which produced a moderate reduction
of the lysis time by 25%), whereas fibrin-dependent
plasminogen activation by tPA was inhibited by up to
30%. Conclusion: ECM components compromise the
chemical and mechanical stability of fibrin as a result of
changes in its ultrastructure.
Keywords: decorin, fibrin, glycosaminoglycan, plasmin,
rheology, shear stress.
Introduction
Fatal outcomes in ischemic cardio- and cerebrovascular
disease are not necessarily a consequence of critical nar-
rowing of the atherosclerotic artery; rather rupture or ero-
sion of the plaque provokes formation of unstable
thrombi, the detachment of which can occlude down-
stream branches of the vascular tree (reviewed in [1]).
Convincing histopathological data support the notion that
such microembolization is the ultimate cause of myone-
crosis in patients dying of acute coronary thrombosis [2].
Although the mechanisms triggering thrombus formation
on atherosclerotic plaques are well characterized, little is
known about the factors that determine the stability of
these thrombi and thus their capacity to form emboli.
Because the solid matrix of thrombi is composed of fibrin
that originates from a blood-borne protein (fibrinogen),
the molecular events at the interface of blood and dam-
aged vascular wall appear to be crucial with respect to
this stability. A major role in plaque disruption is attrib-
uted to matrix metalloproteinases (MMP) expressed in
the vessel wall (reviewed in [3]). Infiltration of thrombi by
leukocytes supplies additional MMPs and serine proteases
(e.g. neutrophil elastase) at this interface (reviewed in [4]).
We have recently demonstrated that such cell- (MMP8,
MMP9, elastase) and thrombus-related (thrombin, plas-
min) proteolytic activity results in clearance of the glyco-
saminoglycans (GAGs) and modification of the
extracellular matrix protein (ECM) structure in the arte-
rial wall [5]. Based on these findings, we hypothesized that
vascular wall components released through proteolysis
Correspondence: Krasimir Kolev, Semmelweis University, Depart-
ment of Medical Biochemistry, 1094 Budapest, T}uzolto u. 37-47,
Hungary.
Tel.: +36 1 4591500/60035; fax: +36 1 2670031.
E-mail: Krasimir.Kolev@eok.sote.hu
Received 13 August 2012, accepted 10 December 2012
© 2012 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 11: 529–538 DOI: 10.1111/jth.12112
could modify the stability of the fibrin matrix formed at
the thrombus/vessel wall interface. Both mechanical sta-
bility and susceptibility to the action of the tissue plasmin-
ogen activator (tPA)/plasminogen system may be affected
(reviewed in [6]). In the present study we addressed the
stability of fibrin matrices co-polymerized in vitro with
vascular proteins, or their fragments, and GAG side
chains, selected either because of their abundance (type I
and III collagens are the major ECM proteins of the
arteries [7,8]) or known effects in blood coagulation and
fibrinolysis (decorin [9,10], chondroitin sulfate and derma-
tan sulfate [11]).
Materials and methods
Human fibrinogen (plasminogen free) was the product
of Calbiochem (La Jolla, CA, USA). This preparation
contained low levels of contaminating factor (F)XIII,
the activity of which resulted in depletion of c-chain
monomers in reducing SDS polyacrylamide electropho-
resis within 1 h after clotting at the thrombin and
CaCl2 concentrations used in these experiments. In the
absence of CaCl2 (in the rheological assay), no c-dimers
could be detected within 30 min. The chromogenic sub-
strates for plasmin, Spectrozyme-PL (H-D norleucyl-
hexahydrotyrosyl-lysine-p-nitroanilide) and for thrombin,
Spectrozyme-TH (H-D-hexahydrotyrosyl-L-alanyl-L-argi-
nine-p-nitroanilide) were from American Diagnostica
(Pfungstadt, Germany), and tPA was from Boehringer
Ingelheim (Germany). Bovine thrombin was purchased
from Serva (Heidelberg, Germany) and was further
purified by ion-exchange chromatography on sulfopro-
pyl-Sephadex yielding a preparation with a specific
activity of 2100 IU mg1 [12]. Dermatan sulfate and
chondroitin sulfate were from Sigma-Aldrich Kft.
(Budapest, Hungary). Collagen G was from Biochrom
AG (Berlin, Germany). Recombinant human decorin
core protein was a product of R&D Systems (Abing-
don, England). Blood was collected from healthy volun-
teers with venipuncture in 10 mM trisodium citrate
(final concentration) and after a 10-min centrifugation
at 2000 9 g the top three-quarters of the plasma layer
was used for the measurements within 4 h.
Purification of fully glycosylated decorin
Published protocols were used for the purification of full-
length glycosylated decorin (aorta decorin) [13], with modi-
fications. Freshly cut bovine aorta slices were immediately
frozen and stored at 80 °C in 2-methylbutane. Thawed
aorta pieces were homogenized in 4 M guanidine hydro-
chloride, 50 mM sodium acetate pH 5.6 buffer containing
5 mM benzamidine, 100 mM e-aminocaproic acid, 10 mM
EDTA 1 mM phenylmethanesulfonyl fluoride (10 mL
extraction buffer g1 tissue). After an overnight incuba-
tion, the extract was centrifuged at 4 °C, 10 000 9 g for
1 h and the supernatant was dialyzed at 4 °C overnight
against 50 mM sodium-acetate pH 6.0 buffer containing
8 M urea, 200 mM NaCl, 0.1% Triton-X-100 (buffer D).
The dialyzed extract was batch adsorbed with buffer D
equilibrated Q-Sepharose and stirred for 2 h at 4 °C. A Q-
Sepharose column was washed with five column volumes
of buffer D, and step elution performed with 0.5–1.2 M
NaCl in buffer D. Fractions were analyzed with alcian-
blue staining after electrophoresis in polyacrylamide gel
(SDS-PAGE). Proteoglycan-containing fractions were
pooled and dialyzed overnight at 4 °C against 50 mM
sodium acetate pH 6.0 buffer containing 7 M urea, 100 mM
NaCl (buffer D2). A DEAE-Sepharose column was equili-
brated with 10 volumes of buffer D2 and mixed with the
dialyzed fractions. After washing the column with 5 col-
umn volumes of D2, gradient elution was carried out with
0.3–1.2 M NaCl in D2. Glycosaminoglycan containing
fractions were pooled and dialyzed against 50 mM sodium
acetate pH 6.0 buffer containing 1.5 M ammonium-sulfate
(buffer D3) overnight at 4 °C. An Octyl-Sepharose column
was washed with 10 column volumes of buffer D3, mixed
with the proteoglycan-containing dialyzed fractions,
washed with 5 column volumes of buffer D3 and eluted
with a 1.5–0 M ammonium-sulfate gradient. Fractions were
analyzed after SDS-PAGE with alcian blue staining and
anti-decorin antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Decorin-containing fractions were
dialyzed in 10 mM HEPES pH 7.4 buffer containing
150 mM NaCl and stored at 20 °C. Decorin was verified
with mass spectrometric analysis of its tryptic peptides on
LCQ-Fleet Ion Trap mass spectrometer (Thermo Scientific,
Karlsruhe, Germany).
Generation of collagen fragments
Recombinant MMP-8 (R&D Systems) at 1 mg mL1 in
50 mM HEPES buffer pH 7.5 containing 150 mM NaCl,
1 mM CaCl2 was activated with 1 mM aminophenylmercu-
ric-acetate (APMA) at 37 °C for 1 h. Collagen G
(90:10% mixture of collagen I and III) was digested with
the activated enzyme at 37 °C for 8 h (1 mg collagen in
1 mL reaction volume in the same buffer). The process
was stopped with 30 lL 50 mM HEPES, 45 mM EGTA
pH 8.0. This digestion resulted in collagen fragments in
the range of 20–60 kDa as verified with silver staining
after SDS-PAGE.
Turbidimetric fibrinolytic assays
In 96-well microtiter plates, 6 lM fibrinogen in 10 mM
HEPES buffer pH 7.4 containing 150 mM NaCl, 2 mM
CaCl2 and collagen fragments/decorin core protein/aorta
decorin/dermatan sulfate/chondroitin sulfate were mixed
with 20 nM thrombin and 6 nM plasmin in a total volume
of 100 lL. Clot formation and dissolution was followed
by measuring the light absorbance at 340 nm at 37 °C
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with a Zenyth 200rt microplate spectrophotometer. The
lysis time (t1/2), defined as the time needed to reduce the
turbidity of the clot to a half-maximal value, was used as
a quantitative parameter of fibrinolytic activity. In a preli-
minary series of experiments a range of additive concen-
trations between 1 and 200 lg mL1 was screened in this
assay and the minimal concentrations yielding significant
differences in the lysis time were selected for more
detailed investigation (2 lg mL1 for the two forms of
decorin and 50 lg mL1 for the rest of the additives). In
certain cases, plasma containing 50 ng mL1 tPA was
clotted with 15 nM thrombin and 12.5 mM CaCl2.
Scanning electron microscopic studies
Fibrin clots of 50 lL volume were prepared in duplicate:
6 lM fibrinogen in 10 mM HEPES buffer pH 7.4 contain-
ing 150 mM NaCl and 2 mM CaCl2 was clotted with
20 nM thrombin at 37 °C for 1 h, with or without vessel
wall proteins/glycosaminoglycans at final concentrations
50 lg mL1 for collagen fragments, dermatan sulfate or
chondroitin sulfate and 50 nM for decorin core protein or
aorta decorin. Clots were washed repeatedly with 0.5%
Triton X-100 and placed in 100 mM Na-cacodylate pH
7.2 for 1 h. After fixation in 1% glutaraldehyde for 1 h,
the samples were dehydrated in a series of ethanol dilu-
tions (20–50–70–85–96%, 5 min each), 1:1 mixture of
96% ethanol:acetone and finally with pure acetone, fol-
lowed by critical point drying with CO2 in an E3000 Crit-
ical Point Drying Apparatus (Quorum Technologies,
Newhaven, UK). The samples were mounted on adhesive
carbon discs, sputter coated with gold in SC7620 Sputter
Coater (Quorum Technologies) and images were taken
with scanning electron microscope EVO40 (Carl Zeiss
GmbH, Oberkochen, Germany). The scanning electron
microscopic (SEM) images were analyzed to determine
the diameter of the fibrin fibers using self-designed pro-
gram functions running under the Image Processing Tool-
box v. 8.0 of Matlab 7.14.0.739 (R2012a) (The
Mathworks, Natick, MA) as previously described [14].
Plasminogen activation assay
In 96-well microtiter plates, 3.3 lM fibrinogen in 10 mM
HEPES buffer pH 7.4 containing 150 mM NaCl, 1.5 mM
CaCl2, 75 nM plasminogen and vessel wall proteins or gly-
cosaminoglycans (at concentrations given above for the
SEM samples) was clotted with 25 nM thrombin in a vol-
ume of 80 lL. After 45 min at 37 °C, 60 lL of 14 nM tPA
and 0.6 mM Spectrozyme-PL in 10 mM HEPES, 150 mM
NaCl pH 7.4 were placed on the surface of the clot. The
forming plasmin generated p-nitroaniline, the absorbance
of which was continuously recorded at 405 nm (A405) with
a Zenith 200rt spectrophotometer (Anthos Labtec Instru-
ments GmbH, Salzburg, Austria). The measured values
were plotted vs. time squared (t2) yielding a linear relation-
ship according to the equation DA405 = 0.5ek1kcat[tPA] t
2
[15], where e = 12.6 mM1 cm1 is the extinction coefficient
of p-nitroaniline [16], k1 = 350 min
1 is the turn-over num-
ber of plasmin on Spectrozyme-PL [16], kcat and [tPA] are
the catalytic constant for plasminogen activation and the
concentration of tPA in the reactive layer on the surface of
fibrin, respectively [17]. The term Vapp = kcat[tPA] is
equivalent to the apparent maximal rate of plasminogen
activation in the reactive layer of fibrin and was determined
from linear regression according to the abovementioned
equation (Curve fitting toolbox v. 3.2.1 of Matlab 2012a).
Evaluation of fibrin rigidity
Fibrinogen at 7.4 lM in 10 mM HEPES pH 7.4 buffer
containing 150 mM NaCl and the investigated ECM com-
ponents at final concentrations of 50 nM for aorta decorin
and decorin core protein or 50 lg mL1 for collagen
fragments, dermatan sulfate and chondroitin sulfate was
mixed with 10 nM thrombin and 410 lL of the clotting
mixture was transferred to the stationary plate of HA-
AKE RheoStress 1 oscillation rheometer (Thermo Scien-
tific) thermostatted at 37 °C. The cone (Titanium, 2°
angle, 35 mm diameter) of the rheometer was brought to
the gap position and shear strain (c) of 0.015 was
imposed exactly at 2 min after the addition of thrombin.
Measurements of storage modulus (G’) and loss modulus
(G’’) were taken at 1 Hz in the course of 15 min with
HAAKE RHEOWIN data manager software v. 3.50.0012
(Thermo Scientific) [18]. After this 15-min clotting phase,
determination of the flow limit of the fibrin gels was per-
formed on the same samples by increasing the applied
shear stress (τ) from 0.01 to 500.0 Pa stepwise in 150 s
and measurements of the resulting strain were used for
calculation of the viscosity modulus (the critical shear
stress τ0 determined by extrapolation of the fall in viscos-
ity to 0 was used as indicator of the gel/fluid transition in
the fibrin structure).
Confocal microscopic imaging
Fibrin clots were prepared from 6 lM fibrinogen, 2% of
which was Alexa Fluor 546-conjugated fibrinogen (Invi-
trogen Life Technologies, Budapest, Hungary) in 10 mM
HEPES buffer pH 7.4 containing 150 mM NaCl, 2 mM
CaCl2, 1.5 lM plasminogen and the tested additives with
16 nM thrombin for 30 min at room temperature in sterile,
uncoated IBIDI VI 0.4 l-slides (Ibidi GmbH, Martinsried,
Germany). Thereafter 4 lg mL1 tPA-YFP (tPA with Yel-
low Fluorescent Protein fused to its C-terminal expressed
using pFastBac-tPA as previously described) [14] was
added to the edge of the clot and the fluorescence (excita-
tion wavelength 488 nm, emission wavelength 525 nm for
tPA-YFP detection and excitation wavelength 543 nm,
emission wavelength 575 nm for Alexa546-fibrinogen
detection) was monitored with Confocal Laser Scanning
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System LSM710 (Carl Zeiss GmbH) taking sequential
images of the fluid-fibrin interface at a distance of approxi-
mately 50 lm from the chamber surface with identical
exposures and laser intensities using a Plan-NeofluarX10/
0.5 objective.
Statistical analysis
The distribution of the data on fiber diameter was ana-
lyzed according to an algorithm used previously [19]: the-
oretical distributions were fitted to the empirical data sets
and compared using Kuiper test and Monte Carlo simula-
tion procedures. The statistical evaluation of other experi-
mental measurements in this study was performed with
the Kolmogorov–Smirnov test (Statistics Toolbox 8.0 of
Matlab R2012a).
Results
To model the impact of ECM components on the lytic
susceptibility of fibrin formed in the immediate vicinity of
proteolytically modified blood vessel walls, composite
clots were prepared from fibrin and purified proteogly-
cans or their fragments. In this experimental setting, when
clotting and fibrinolysis were initiated simultaneously, the
time course of fibrin formation and dissolution reflects
the global stability of fibrin clots exposed to plasmin, the
major fibrinolytic enzyme. The presence of ECM proteins
or glycosaminoglycans at concentration corresponding to
only several per cent of the scaffold-forming fibrin
concentration resulted in a significantly less stable clot
structure, reflected in the shorter lysis time of the compos-
ite clots (Fig. 1 and Table 1). The presence of a sugar
subunit in the structure of the modifier enhances the lytic
susceptibility of the clots, as demonstrated by the differ-
ence in the lysis time for clots with full and core decorin,
whereas the strongest destabilizing effects were related to
the highly negatively charged glycosaminoglycans (chon-
droitin sulfate and dermatan sulfate). Noteworthy differ-
ences were seen in the ascending phase of the turbidity
Fig. 1. Fibrin clot lysis assay. Fibrin clots containing plasmin and
the indicated additives at final concentrations 50 lg mL1 for colla-
gen fragments, dermatan sulfate or chondroitin sulfate and 50 nM
for decorin core protein or aorta decorin were prepared and the
absorbance was continuously measured at 340 nm (turbidity, A340).
Mean values of eight measurements from three independent experi-
ments (continuous lines) and standard deviation (SD) values above
and below mean (dotted lines) are shown. Symbols indicate half-
maximal values of A340 reported as lysis time in Table 1.
Table 1 Clotting and lysis parameters of composite fibrin clots
Additive None fDCN cDCN CF DS CS
Clotting time (min) 5.6  0.3 2.9  0.1* 1.1  0.1* 0.9  0.1* 5.4  0.1 7.1  0.3*
Lysis time (min) 63.9  8.7 34.9  4.4* 47.6  8.9* 30.4  12.2* 25.8  3.1* 28.0  6.4*
Clots containing 6 lM fibrin, 6 nM plasmin and the indicated additives were prepared and the values of the clotting and lysis time were deter-
mined as the time needed to reach half-maximal turbidity on the ascending and descending part of the turbidity curves illustrated in Fig. 1.
The values are reported as mean and standard deviation of at least eight measurements from three independent experiments. fDCN, 50 nM
aorta decorin; cDCN, 50 nM decorin core protein; CF, 50 lg mL1 collagen fragments; DS, 50 lg mL1 dermatan sulfate; CS, 50 lg mL1
chondroitin sulfate. *P < 0.05 according to the Kolmogorov–Smirnov test in comparison to pure fibrin.
Fig. 2. Plasminogen activation on the surface of fibrin. Fibrin clots
containing plasminogen and the indicated additives were prepared
and after the addition of tissue plasminogen activator (tPA) and the
plasmin substrate Spectrozyme-PL the absorbance was continuously
measured at 405 nm (A405). Mean values of eight measurements
from three independent experiments (continuous lines) and standard
deviation (SD) values above and below the mean (dotted lines) are
shown. Inset: Secondary plots of the raw data that are used for the
calculation of the apparent maximal activation rates (Vapp) reported
in Table 2 (DA405=0.5ek1Vappt
2, for symbols see ‘Materials and
methods’).
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curves in Fig. 1 indicating accelerated formation of the
composite clots containing proteins (shorter time to reach
half-maximal turbidity in the presence of collagen frag-
ments, glycosylated or core decorin, Table 1), whereas the
isolated glycosaminoglycans either had no effect (derma-
tan sulfate) or delayed clot formation (chondroitin sul-
fate). Because a potential mechanism of the observed
enhancement in the formation and lysis of the fibrin clots
could be a direct effect on the activity of the enzymes
involved (thrombin and plasmin), their activity was mea-
sured in a fibrin-free system on small peptide substrates
for thrombin and plasmin (Spectrozyme-TH and Spectro-
zyme-PL, respectively). None of the investigated ECM
components applied at the concentrations as in Fig. 1
influenced the enzyme activities in the absence of fibrin
(data not shown).
In the experimental setup used in Fig. 1, plasmin activ-
ity is detected on the same substrate (fibrin) that serves as
a cofactor in tPA-dependent plasminogen activation. Thus
any effects of changes in fibrin structure on the rates of
zymogen activation are complicated by changes in the sus-
ceptibility of modified fibrin as a substrate for plasmin. In
order to identify the isolated effects on plasminogen acti-
vation, plasmin generated on the surface of fibrin was
measured using a small peptide substrate (Spectrozyme-
PL) that can efficiently compete with fibrin and prevents
the digestion of the cofactor (Fig. 2). The apparent maxi-
mal plasminogen activation rate (Vapp) decreased to a
statistically significant degree in the presence of ECM
components; 12–29% reduction in Vapp could be observed
(Table 2). This modest attenuation of plasminogen activa-
tion on the surface of fibrin reflects either decreased
catalytic turnover (kcat) or impaired interfacial pene-
tration ([tPA]) in the modified fibrin structure
(Vapp = kcat[tPA]). If plasminogen was activated in the
absence of fibrin in a two-stage assay [20], the investigated
modifiers did not affect the activation rate precluding
direct effects on tPA (data not shown). The lack of effects
in free solution and the variable inhibition of plasminogen
activation on the fibrin surface pointed to a role for the
modification of fibrin structure in the reactive interface
layer that is known to profoundly affect both tPA and
plasminogen binding to fibrin, an essential determinant of
plasmin generation in fibrin clots [14,21]. The dynamics of
this process was addressed with confocal microscopic
studies using fluorescent tPA-YFP (Fig. 3). In all clots,
tPA-YFP accumulated in a sharp interfacial layer, which
moved as a result of fibrin lysis by the generated plasmin.
The rate of migration of this front (Table 2) correlated
with the rates of plasmin-mediated fibrin lysis (Fig. 1)
rather than with the rate of overall plasmin generation
(Fig. 2). The spatial distribution of the fluorescent tPA in
the rearranging fibrin structure provides a mechanistic
explanation for this effect. One of the modifiers, chondroi-
tin sulfate, resulted in a broader homogenous tPA-rich
band in fibrin, whereas in the presence of the other addi-
tives tPA co-localized with aggregates of partially
degraded fibrin (the coincident green, tPA and red fibrin
fluorescence is seen as yellow grains in Fig. 3). A similar
granular pattern of tPA accumulation coupled to faster
lysis, in spite of slower plasminogen activation has been
previously reported for fibrin composed of thick fibers
[14], suggesting a significant role for the structure of the
fibrin network in these composite clots.
Further structural details underpinning the observed
changes in the enzymatic susceptibility and the tPA-cofac-
tor function of the composite fibrin matrices were investi-
gated using SEM (Fig. 4A). Morphometric analysis of the
SEM images indicated a significant increase in fiber diam-
eter in all cases when fibrin was polymerized in the pres-
ence of protein additives (decorin or collagen fragments).
Although the negatively charged chondroitin sulfate and
dermatan sulfate did not significantly influence the archi-
tecture of the fibrin network individually, fully glycosylat-
ed decorin, containing the same sugar subunits, caused
the most pronounced modification of fibrin structure
(Fig. 4B).
The viscoelastic properties of the composite fibrin clots
were approached using rheological methods (Fig. 5).
Fully glycosylated decorin exerted the most pronounced
effects on the rigidity of fibrin (decrease in the storage
modulus G’ by about 40%) and its susceptibility to struc-
tural rearrangements upon deformation (decrease in the
loss modulus G’’ by about 25%) (Table 3). All other
Table 2 Plasminogen activation on the surface of composite fibrin clots
Additive None fDCN cDCN CF DS CS
Vapp for Pn formation (nM min
1) 0.18  0.007 0.160  0.011* 0.139  0.008* 0.130  0.015* 0.150  0.015* 0.161  0.011*
Relative activation rate of Pg 1 0.87 0.76 0.71 0.82 0.88
Relative migration rate of tPA 1 2.03 1.52 1.54 1.46 1.56
tPA and plasmin substrate Spectrozyme-PL were added to clots containing 3 lM fibrin, 0.1 lM plasminogen and the indicated additives and
the values of the apparent activation rate (Vapp) were determined as the slopes of the plots illustrated in the Inset of Fig. 2. The values are
reported as mean and standard deviation of at least eight measurements from three independent experiments. The relative migration rate of
tPA in lysing fibrin has been calculated from the position of the tPA-YFP-rich layer on the surface of fibrin clots as illustrated in Fig. 3.
fDCN, 50 nM glycosylated aorta decorin; cDCN, 50 nM decorin core protein; CF, 50 lg mL1 collagen fragments; DS, 50 lg mL1 dermatan
sulfate; CS, 50 lg mL1 chondroitin sulfate. *P < 0.05 according to the Kolmogorov–Smirnov test in comparison to pure fibrin.
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modifiers had no effect on G’ and G’’ values (except for a
moderate decrease in G’ related to collagen fragments).
The only parameter that was significantly decreased by all
ECM components (except the core protein of decorin)
was the critical shear stress (τ0) causing an abrupt decline
in viscosity of fibrin (gel/fluid transition) (Table 3).
In order to evaluate the validity of the observed effects
in a more physiological environment, tPA-mediated lysis
of blood plasma clots was examined (Fig. 6). Dermatan
sulfate (at 50 lg mL1) completely blocked the formation
of plasma clots in line with its known potentiating effect
on the inactivation of thrombin by heparin cofactor II
[22–24]. Plasma clots containing all other components
lysed at faster rates following the trend of plasmin-medi-
ated (Fig. 1) and tPA-mediated (Fig. 3) fibrin lysis.
Discussion
The in vitro models applied in this study address the ques-
tion of lytic susceptibility and mechanical stability of
fibrin structures formed when products of limited proteol-
ysis are released from the arterial wall and coincide with
fibrin polymerization. The concentrations of fibrinogen
and the ionic environment used in the present studies cor-
respond to the in vivo conditions found in blood plasma,
whereas the vascular wall components (proteins and their
fragments or glycosaminoglycans) were present in
amounts up to 2.5% by mass of the amount of fibrin.
Thus, the effects reported here require minimal exposure
of ECM components at the site of thrombus formation,
and the concentrations used are reasonable in view of the
massive collagen and decorin deposits observed in primary
atherosclerotic, as well as in restenotic lesions after coro-
nary angioplasty [25] and the extensive proteolytic modifi-
cation of the vascular wall induced by leukocytes [5]. At
present, in spite of qualitative evidence for significant
abundance in atherosclerotic lesions of the ECM compo-
nents investigated in the current study, there are scarce
quantitative data on their concentrations. However, the
example of chondroitin sulfate, which is present at
2 lg mL1 basal concentration in plasma, but at 2-fold
higher concentration when platelets are activated [26], sug-
gests the local concentration could be orders of magnitude
higher, before dilution in several liters of circulating
blood.
The mechanical stability of fibrin structures that form
efficient hemostatic plugs at sites of vessel injury is defi-
nitely compromised if ECM components co-polymerize.
Significantly lower shear stress is needed to liquefy a
fibrin gel in the presence of glycosylated decorin, collagen
fragments, dermatan sulfate or chondroitin sulfate (τ0 in
Table 3). The strongest rheological effects are produced
by fully glycosylated decorin, which also causes the most
pronounced changes in fibrin structure (Fig. 4). In agree-
Fig. 3. Penetration of tissue plasminogen activator (tPA)-YFP into fibrin in the course of lysis. Clots were prepared from fibrinogen containing
Alexa546-labeled fibrinogen, plasminogen and the indicated additives at final concentrations 50 lg mL1 for collagen fragments, dermatan sul-
fate or chondroitin sulfate and 50 nM for decorin core protein or aorta decorin. After 30-min clotting tPA-YFP was added to fibrin and the
fluid/fibrin interface was monitored by confocal laser scanning microscopy using double fluorescent tracing (excitation 488 nm/emission
525 nm for tPA-YFP and excitation 543 nm/emission 575 nm for fibrin). Images are shown for the 25th min after the application of tPA-YFP,
scale bar = 100 lm. The tPA-related fluorescence stains in green, whereas the fibrin is shown in red in these images and selected regions are
digitally magnified four-fold to illustrate the structural pattern of the interface layer. At 0 time the edge of the fibrin clot was approximately at
the same position near the top of each field of observation. The numbers in each panel indicate the distance for penetration of tPA-YFP in the
clot at 25 min (mean and standard deviation from three samples, P < 0.05 for all additives according to the Kolmogorov–Smirnov test in com-
parison to pure fibrin).
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ment with earlier reports [18], thicker fibrin fibers were
coupled to increases in the loss tangent parameter
(tand = G’’/G’) (Table 3). According to the interpretation
of rheological parameters suggested in Ref. [18], the loss
tangent reflects the dissipation of energy originating from
molecular rearrangements in the fibrin network caused by
mechanical forces (dissociation of monomers within pro-
tofibrils or of protofibrils within fibers). This parameter
indicates that in spite of the identical trend of changes
(decrease) in the rigidity (storage modulus G’) and dissi-
pation energy (loss modulus G’’) the fibrin structure soft-
ened by aorta decorin is relatively more susceptible to
rearrangements of fibrin monomers or protofibrils than
pure homogeneous fibrin. Rheology studies were per-
formed in the absence of CaCl2, because our fibrinogen
preparation contained factor FXIII and, as also shown
by others [18], in the presence of physiological concentra-
tions of CaCl2 FXIIIa-dependent cross-linking continues
for several hours. Thus, the G’, G’’ values do not reach a
plateau by 2 h, in contrast to the situation seen without
CaCl2 (Fig. 5). In order to obtain reliable estimates for
parameters of the mechanical properties of the clots we
chose to perform the rheology measurements in the
absence of CaCl2 and FXIIIa-dependent cross-linking. As
other techniques used in these studies (light absorbance in
turbidimetry, fluorescence intensity in confocal micros-
copy, fiber diameter in scanning electron microscopy)
were not sensitive to cross-linking, physiological concen-
trations of CaCl2 were included in these systems. In view
of recent data that the antifibrinolytic function of FXIII
is exclusively expressed through a2-plasmin inhibitor
cross-linking [27], the similar pattern of results observed
Fig. 4. Ultrastructure of the fibrin network. (A) Fibrinogen (4.8 lM) without any additive (i) or containing 50 nM fully glycosylated decorin;
and (ii) was mixed with thrombin and after 1 h clots were fixed with glutaraldehyde, dehydrated and examined with scanning electron micro-
scopy (SEM). Scale bar = 1 lm. (B) Morphometric analysis of fibrin structure. Fibrin clots containing the indicated additives were prepared
and SEM images taken as illustrated in panel A. The diameter of 300 fibers was measured and their empiric (black histograms) as well as best-
fitted theoretical (gray curves) probability density function (PDF) was determined. Median values and the interquartile range are shown for the
theoretical distributions of the diameter values.
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in assay systems that contain FXIIIa, but no a2-plasmin
inhibitor (fibrin clots in Figs. 1 and 3) or both FXIIIa
and a2-plasmin inhibitor (plasma clots in Fig. 6) suggests
that the reported ECM effects are independent of the
function of FXIII in fibrinolysis.
Functional assays were investigated that could discrimi-
nate effects in the two stages of the classic fibrinolytic
pathway: plasminogen activation by tPA on a fibrin tem-
plate and fibrin dissolution by plasmin (reviewed in [28]).
When plasminogen was activated by tPA applied to the
surface of fibrin clots (Fig. 2), a low-degree inhibition of
activation was observed if clots contained various compo-
nents derived from the vessel wall. MMP-8-digested colla-
gen fragments and decorin core protein resulted in the
strongest decrease in the apparent maximal rate of activa-
tion by 25–30% (Table 2), whereas the presence of glyco-
saminoglycans (either in free form or attached to decorin)
moderated this effect to 12–18% inhibition. Because none
of the investigated modifiers affected plasminogen activa-
tion in the absence of fibrin (data not shown), the
observed effects could be explained by modulation of the
interfacial phenomena on the surface of the composite
clots. According to our earlier data from identical activa-
tion assays [14], thicker fibers are coupled to impaired co-
factor function of fibrin in tPA-dependent plasminogen
activation. In agreement with this general trend, in the
present study, we observed the strongest inhibition of
plasminogen activation in fibrin matrices containing colla-
gen fragments and decorin core protein, which caused sig-
nificant increases in the fiber diameter (Fig. 4). However,
Fig. 5. Modification of the viscoelastic properties of fibrin by extra-
cellular matrix components. (A) Fibrinogen (7.4 lM) containing
50 nM decorin (fully glycosylated aorta or core protein) was mixed
with thrombin and the storage modulus (G’, continuous line) and
the loss modulus (G’’, crossed line) were measured using an oscilla-
tion rheometer. (B) After 15-min clotting, stepwise increasing shear
stress τ was applied to fibrin formed in the gap space of the oscilla-
tion rheometer and viscosity (g) was measured. The critical values τ0,
which define the gel/fluid transition of fibrin, are shown in Table 3.
Table 3 Viscoelasticity parameters of composite fibrin clots
Additive None fDCN cDCN CF DS CS
G’ (Pa) 54.29  12.98 33.20  3.68* 47.04  0.62 40.70  2.88* 41.13  10.68 47.81  9.20
G’’ (Pa) 4.58  0.90 3.38  0.50* 4.07  0.43 3.83  0.38 3.77  0.65 4.45  0.74
G’’/G’ 0.086  0.015 0.102  0.006* 0.086  0.008 0.094  0.008 0.093  0.007 0.094  0.006
τ 0 (Pa) 154.42  24.34 85.58  10.65* 130.25  7.85 95.56  9.40* 103.89  8.50* 111.01  15.81*
Clots containing 7.3 lM fibrin and the indicated additives were prepared and their rigidity was evaluated in an oscillation rheometer. The val-
ues of the storage modulus (G’), the loss modulus (G’’) and the loss tangent (tand = G’’/G’) are shown for the 15th min of clotting, when they
reached a plateau, whereas the critical shear stress τ0 was determined by extrapolation of the fall in viscosity to 0 as illustrated in Fig. 5B.
Mean and standard deviation of at least three measurements are shown. fDCN, 50 nM glycosylated aorta decorin; cDCN, 50 nM decorin core
protein; CF, 50 lg mL1 collagen fragments; DS, 50 lg mL1 dermatan sulfate; CS, 50 lg mL1 chondroitin sulfate. *P < 0.05 according to
the Kolmogorov–Smirnov test in comparison to pure fibrin.
Fig. 6. Plasma clot lysis. Citrated human plasma was supplemented
with 50 ng mL1 tissue plasminogen activator (tPA) and the indi-
cated additives at final concentrations 50 lg mL1 for collagen frag-
ments, dermatan sulfate or chondroitin sulfate and 50 nM for
decorin core protein or aorta decorin. Clotting was initiated with
CaCl2 and thrombin at 12.5 mM and 15 nM final concentrations,
respectively, and the absorbance was continuously measured at
340 nm (turbidity, A340). Mean values of eight measurements from
three independent experiments (continuous lines) and standard devia-
tion (SD) values above and below the mean (dotted lines) are shown.
Symbols indicate half-maximal values of A340, P < 0.05 for all addi-
tives according to the Kolmogorov–Smirnov test in comparison to
additive-free clot lysis time.
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the thickest fibers seen in the presence of fully glycosylat-
ed aorta decorin produced less pronounced inhibition,
which is probably related to independent effects of the
negatively charged glycosaminoglycan side chains result-
ing in enhanced penetration or efficient clustering of tPA
in the interfacial reactive layer of fibrin. Our data derived
from the distribution of fluorescent tPA in the interfacial
layer of lysing fibrin (Fig. 3) provides evidence that both
of these hypothetic mechanisms are operational; the for-
mer in clots containing chondroitin sulfate, the latter with
the other investigated ECM components.
The second stage of the fibrinolytic process, the diges-
tion of fibrin by plasmin, was more profoundly affected
by the components of the ECM investigated in these stud-
ies (Fig. 1). In all cases the composite clots lysed faster
than pure fibrin, but the increase in rate depended on the
type of modifier. Decorin core protein shortened the lysis
time by 25%, whereas the presence of fully glycosylated
aorta decorin, collagen fragments or isolated glycosami-
noglycans resulted in approximately two-fold faster lysis
(Table 1). The general trend was that faster lysis was cou-
pled to faster clotting in the presence of protein modula-
tors, whereas glycosaminoglycans enhanced plasmin
catalyzed lysis in spite of the unaltered or even delayed
clotting phase. In line with our recent findings [14], and
earlier work (reviewed in [6]), the coarse fibrin structures
(thicker fibers, Fig. 4) formed in the presence of decorin
core protein, aorta decorin or collagen fragments were
lysed faster. However, in the case of isolated dermatan
sulfate and chondroitin sulfate no significant structural
alterations could be detected in the ultrastructure of fibrin
with SEM (Fig. 4) in spite of a significant enhancement
in lysis (Fig. 1). It is noteworthy that the lack of an effect
on the fibrin structure was accompanied by differential
effects on the kinetics of clotting (Fig. 1); in contrast to
the accelerated fibrin formation in the presence of protein
modifiers, the same glycosaminoglycans either did not
change or prolonged the clotting time (Table 1). Because
we could not detect any effects on thrombin activity mea-
sured on a small synthetic chromogenic substrate (data
not shown), an alternative background of the modified
clotting profiles should be sought in the macromolecular
nature of the fibrinogen substrate. For example, in the lit-
erature [9,29] there is some evidence for interactions of
fibrinogen and ECM components that could change the
kinetics of fibrin monomer formation and/or polymeriza-
tion, but clarification of the exact mechanism requires
further studies.
As our data demonstrate that fibrin lysis by plasmin
(Fig. 1) and plasminogen activation (Fig. 2) are affected
in a discordant manner by the modulators under investi-
gation when present in the clot, the overall outcome can-
not be predicted when the two stages of fibrinolysis
operate simultaneously. To clarify this issue two types of
assay were performed, in which clot lysis was initiated by
tPA/plasminogen (Figs. 3 and 6). These data show that
the effects exerted on plasmin-mediated lysis dominate
the overall fibrinolytic process, which is accelerated by all
examined modulators in spite of the modest inhibition of
plasminogen activation. Importantly, this enhanced lytic
susceptibility is preserved even at physiological levels of
blood plasma inhibitors (Fig. 6).
In summary, our present study indicates that in spite
of subtle differences in mechanism, vascular wall com-
ponents entrapped in the structure of fibrin generally
compromise the mechanical and chemical stability of
fibrin, they increase its susceptibility to shear stress and
to plasmin, the major fibrinolytic protease. These effects
require minimal concentrations of modulators. In an
earlier study [10] thinner fibers and mildly suppressed
tPA-dependent fibrinolysis were reported in the presence
of recombinant decorin. However, the fibrin used in
that work was prepared with 20-fold lower thrombin
and 2-fold higher Ca2+ concentrations (conditions
known to profoundly affect the structure and lytic sus-
ceptibility of fibrin, [14]), and the decorin concentration
was 10-fold higher. In addition, the recombinant deco-
rin used in that study was not glycosylated in contrast
to the natural aorta decorin used by us and, as clearly
demonstrated by the present data, some functional
effects in fibrinolysis depend on the nature of the gly-
cosaminoglycan.
Concerning the in vivo implications of the reported
results, differences between physiological wound healing
and pathological thrombi in ruptured atherosclerotic pla-
ques should be considered. Hemostatic plugs are formed
over acutely injured vessel wall when blood makes con-
tact with largely intact (except for the localized mechani-
cal damage) subendothelial structures. In contrast, the
atherosclerotic plaque is a focus of chronic inflammation
and thus, after rupture, blood is exposed to an environ-
ment that has been extensively processed by proteases
and other hydrolases released from inflammatory cells.
Hence, the processes investigated here are probably
observed in pathological thrombi. Nevertheless, athero-
sclerotic plaque lesions are sites of a dynamically chang-
ing structure because of altered proteoglycan synthesis
[30,31] and proteolytic destruction [3] and additional stud-
ies are required to investigate the quantity and nature of
the protein and glycosaminoglycan modulators in thrombi
attached to, or derived from, atherosclerotic plaques.
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